SaponiQx Announces It Achieved A Milestone In Scaling Up Of STIMULON Cultured Plant Cell Adjuvant
Portfolio Pulse from Benzinga Newsdesk
SaponiQx has announced successful production of STIMULON cpcQS-21, a cultured plant cell adjuvant with confirmed biochemical comparability to traditional bark extract-derived adjuvant. The company has submitted a Master File for STIMULON cpcQS-21 to the U.S. FDA for reference by partners as part of regulatory submissions. SaponiQx is also collaborating with Ginkgo Bioworks to drive innovation in its adjuvant pipeline through generative molecular design.

August 09, 2023 | 12:40 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
SaponiQx's successful production of STIMULON cpcQS-21 and its submission to the FDA could potentially impact Agenus Inc. (AGEN), if they are partners or stakeholders.
The news does not provide specific details on how Agenus Inc. (AGEN) is related to SaponiQx's STIMULON cpcQS-21 production or FDA submission. Therefore, the potential impact is uncertain.
CONFIDENCE 50
IMPORTANCE 50
RELEVANCE 50